Global Head, Digital BD&L, Partnership, & Innovation
Jeremy Sohn has extensive experience as a digital health investor and serial software entrepreneur. As Global Head of Digital BD&L, Jeremy oversees three teams: 1) dRx Capital investment portfolio 2) a digital business development and licensing transactions team, and 3) Novartis Biome, an internal accelerator supporting innovation partnerships across the globe. At Novartis, Jeremy has led and/or supported multiple, first-in-pharma initiatives, including: in-licensing the first prescription digital therapeutic, investment in the first decentralized clinical trial company, designing Novartis’ intelligent salesforce optimization platform, implementing Novartis’ next-generation AI / ML strategy, and driving patient centricity and clinical trial optimization.
Previously, Jeremy was Managing Director at MPM Capital where he founded and invested in two companies, CentrosHealth, acquired by Clinical Ink, and TriNetX, acquired by The Carlyle Group. He co-founded GrapeVine, a social networking company that optimizes how organizations connect with their target communities. He was COO and VP, Strategy & Corporate Development for North Plains Systems, a digital asset management company, where he led the company's growth and eventual sale to Accel-KKR. He also co-founded an open-source operating system company, Wasabi Systems. Jeremy holds a B.A. from Princeton University. He spends as much free time as possible with family and friends, is an avid runner, and loves experiencing life through food.
Jeremy is a board observer at Cota Healthcare, Pear Therapeutics, and SomaLogic, and is based out of Cambridge, Massachusetts.